 JUPITER, FL ACCESSWIRE April 30, 2020 Dyadic International, Inc. Dyadic DYAI, a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for quarter ended March 31, 2020 after the market close on Thursday, May 14, 2020 and it will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results. To access the replay which will expire May 28, 2020, dial 1 877 481-4010 U.S. or Canada or 1 919 882-2331 International and enter replay pass code: 34441. Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica formerly Myceliophthora thermophila, named C1. 